Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
Ipilimumab, a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody that potentiates antitumor T-cell responses, has demonstrated improved survival in previously treated and treatment-naïve patients with unresectable stage III/IV melanoma. Survival benefit has also been shown in dive...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Journal of Skin Cancer |
| Online Access: | http://dx.doi.org/10.1155/2013/423829 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553364179648512 |
|---|---|
| author | Bartosz Chmielowski |
| author_facet | Bartosz Chmielowski |
| author_sort | Bartosz Chmielowski |
| collection | DOAJ |
| description | Ipilimumab, a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody that potentiates antitumor T-cell responses, has demonstrated improved survival in previously treated and treatment-naïve patients with unresectable stage III/IV melanoma. Survival benefit has also been shown in diverse patient populations, including those with brain metastases. In 2011, ipilimumab (3 mg/kg every 3 weeks for 4 doses) was approved by the Food and Drug Administration for unresectable or metastatic melanoma. Ipilimumab can induce novel response patterns for which immune-related response criteria have been proposed. irAEs are common but are usually low grade; higher grades can be severe and life-threatening. irAEs are usually manageable using established guidelines emphasizing vigilance and prompt intervention. This agent provides an additional therapeutic option in metastatic melanoma, and guidelines for management of adverse events facilitate clinical implementation of this new agent. |
| format | Article |
| id | doaj-art-e2f3683bb8ac46b3b7f7ec1f110f0b0e |
| institution | Kabale University |
| issn | 2090-2905 2090-2913 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Skin Cancer |
| spelling | doaj-art-e2f3683bb8ac46b3b7f7ec1f110f0b0e2025-02-03T05:54:15ZengWileyJournal of Skin Cancer2090-29052090-29132013-01-01201310.1155/2013/423829423829Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic MelanomaBartosz Chmielowski0Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USAIpilimumab, a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody that potentiates antitumor T-cell responses, has demonstrated improved survival in previously treated and treatment-naïve patients with unresectable stage III/IV melanoma. Survival benefit has also been shown in diverse patient populations, including those with brain metastases. In 2011, ipilimumab (3 mg/kg every 3 weeks for 4 doses) was approved by the Food and Drug Administration for unresectable or metastatic melanoma. Ipilimumab can induce novel response patterns for which immune-related response criteria have been proposed. irAEs are common but are usually low grade; higher grades can be severe and life-threatening. irAEs are usually manageable using established guidelines emphasizing vigilance and prompt intervention. This agent provides an additional therapeutic option in metastatic melanoma, and guidelines for management of adverse events facilitate clinical implementation of this new agent.http://dx.doi.org/10.1155/2013/423829 |
| spellingShingle | Bartosz Chmielowski Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma Journal of Skin Cancer |
| title | Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma |
| title_full | Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma |
| title_fullStr | Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma |
| title_full_unstemmed | Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma |
| title_short | Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma |
| title_sort | ipilimumab a first in class t cell potentiator for metastatic melanoma |
| url | http://dx.doi.org/10.1155/2013/423829 |
| work_keys_str_mv | AT bartoszchmielowski ipilimumabafirstinclasstcellpotentiatorformetastaticmelanoma |